Between October 18–21, this website will move to a new web address (from health.gov to odphp.health.gov). During that time, some functions might not work as expected. We appreciate your patience and understanding as we’re working to make this transition as smooth as possible.

U.S. Department of Health and Human Services Office of Disease Prevention and Health Promotion

Guidance Document: CVM GFI #152 Evaluating the Safety of Antimicrobial New Animal Drugs with Regard to their Microbiological Effects on Bacteria of Human Health Concern

About this resource:

HHS Non-systematic Review

Source: Food and Drug Administration

Last Reviewed: August 2018

Workgroups: Food Safety Workgroup

This webpage gives guidance around evaluating the risks of antimicrobial new animal drugs for food safety and human health. The webpage links to the full guidance document, which is for industry professionals and addresses antimicrobial new animal drugs and their impact on bacteria in food-producing animals.

Read more about this resource

Objectives related to this resource (2)

Prevent an increase in the proportion of nontyphoidal Salmonella infections that are resistant to multiple drug classes — FS‑05
Baseline only
Prevent an increase in the proportion of macrolide antibiotic-resistant Campylobacter infections — FS‑06
Baseline only

Suggested Citation

1.

Center for Veterinary Medicine, U.S. Food and Drug Administration. (2003). CVM GFI #152 evaluating the safety of antimicrobial new animal drugs with regard to their microbiological effects on bacteria of human health concern. Retrieved from https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-152-evaluating-safety-antimicrobial-new-animal-drugs-regard-their-microbiological-effects